Acromegaly

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 5, 2009, Pages 555-574

  Chanson, Philippe ^a   Salenave, Sylvie ^a   Kamenicky, Peter ^a   Cazabat, Laure ^a   Young, Jacques ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

acromegaly; growth hormone; insulin like growth factor I; pegvisomant; pituitary; somatostatin analogues

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; CLINICAL FEATURE; DRUG RECEPTOR BINDING; ENDOCRINE SURGERY; GENE MUTATION; GENETIC DISORDER; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HUMAN; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; ADENOMA; BIOLOGICAL MODEL; CARCINOMA; PROFESSIONAL PRACTICE; SECRETION;

ACROMEGALY; ADENOMA; CARCINOMA; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; MODELS, BIOLOGICAL; PROFESSIONAL PRACTICE;

EID: 72049089863     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2009.05.010     Document Type: Review

References (98)

1. Holdaway I.M., and Rajasoorya C. Epidemiology of acromegaly. Pituitary 2 (1999) 29-41
2. Daly A.F., Rixhon M., Adam C., et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 4769-4775
3. Schneider H.J., Sievers C., Saller B., et al. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clinical Endocrinology 69 (2008) 432-435
4. Nabarro J.D. Acromegaly. Clinical Endocrinology 26 (1987) 481-512
5. Ezzat S., Forster M.J., Berchtold P., et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 73 (1994) 233-240
6. Melmed S. Acromegaly. In: Melmed S. (Ed). The pituitary (2002), Blackwell Science Inc., Malden, Mas, USA 419-454
7. Nachtigall L., Delgado A., Swearingen B., et al. Changing patterns in diagnosis and therapy of acromegaly over two decades. The Journal of Clinical Endocrinology and Metabolism 93 (2008) 2035-2041
8. Asa S.L., Kovacs K.T., and Melmed S. Functional anatomy of the hypothalamic pituitary axis. In: Melmed S. (Ed). The pituitary. 2nd edn. (2002), Blackwell Science Inc., Malden, Mas, USA 3-44
9. Heaney A.P., and Melmed S. Molecular targets in pituitary tumours. Nature Reviews Cancer 4 (2004) 285-295
10. Beck-Peccoz P., Bassetti M., Spada A., et al. Glycoprotein hormone alpha-subunit response to growth hormone (GH)-releasing hormone in patients with active acromegaly. Evidence for alpha-subunit and GH coexistence in the same tumoral cell. The Journal of Clinical Endocrinology and Metabolism 61 (1985) 541-546
11. Beck-Peccoz P., Brucker-Davis F., Persani L., et al. Thyrotropin-secreting pituitary adenomas. Endocrine Reviews 17 (1996) 610-638
12. Socin H.V., Chanson P., Delemer B., et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. European Journal of Endocrinology 148 (2003) 433-442
13. Melmed S. Medical progress: acromegaly. The New England Journal of Medicine 355 (2006) 2558-2573
14. Herman V., Fagin J., Gonski R., et al. Clonal origin of pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism 71 (1990) 1427-1430
15. Vallar L., Spada A., and Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330 (1987) 566-568
16. Vlotides G., Eigler T., and Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocrine Reviews 28 (2007) 165-186
17. Filippella M., Galland F., Kujas M., et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clinical Endocrinology 65 (2006) 536-543
18. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. The Journal of Clinical Investigation 112 (2003) 1603-1618
19. Asa S.L., and Ezzat S. The pathogenesis of pituitary tumours. Nature Reviews Cancer 2 (2002) 836-849
20. Chanson P., Salenave S., Droumaguet C., et al. Rare causes of acromegaly. In: Wass J.A. (Ed). Acromegaly: a handbook of history, current therapy and future prospects (2009), Bioscientifica Ltd, Bristol, UK 70-98
21. Chanson P., and Salenave S. Acromegaly. Orphanet Journal of Rare Diseases 3 (2008) 17
22. Colao A., Ferone D., Marzullo P., et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 25 (2004) 102-152
23. Giustina A., Casanueva F.F., Cavagnini F., et al. Diagnosis and treatment of acromegaly complications. Journal of Endocrinological Investigation 26 (2003) 1242-1247
24. Melmed S., Colao A., Barkan A., et al. Guidelines for acromegaly management: an update. The Journal of Clinical Endocrinology and Metabolism 94 (2009) 1509-1517
25. Molitch M.E. Clinical manifestations of acromegaly. Endocrinology and Metabolism Clinics of North America 21 (1992) 597-614
26. Danzig J. Acromegaly. BMJ 335 (2007) 824-825
27. Mazziotti G., Bianchi A., Bonadonna S., et al. Prevalence of vertebral fractures in men with acromegaly. The Journal of Clinical Endocrinology and Metabolism 93 (2008) 4649-4655
28. Miller A., Doll H., David J., et al. Impact of musculoskeletal disease on quality of life in long-standing acromegaly. European Journal of Endocrinology 158 (2008) 587-593
29. Jenkins P.J., Sohaib S.A., Akker S., et al. The pathology of median neuropathy in acromegaly. Annals of Internal Medicine 133 (2000) 197-201
30. Tagliafico A., Resmini E., Nizzo R., et al. The pathology of the ulnar nerve in acromegaly. European Journal of Endocrinology 159 (2008) 369-373
31. Chanson P., Timsit J., Masquet C., et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Annals of Internal Medicine 113 (1990) 921-925
32. Kamenicky P., Viengchareun S., Blanchard A., et al. Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. Endocrinology 149 (2008) 3294-3305
33. Maison P., Demolis P., Young J., et al. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clinical Endocrinology 53 (2000) 445-451
34. Colao A., Baldelli R., Marzullo P., et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 193-199
35. Jaffrain-Rea M.L., Moroni C., Baldelli R., et al. Relationship between blood pressure and glucose tolerance in acromegaly. Clinical Endocrinology 54 (2001) 189-195
36. Sacca L., Cittadini A., and Fazio S. Growth hormone and the heart. Endocrine Reviews 15 (1994) 555-573
37. Clayton R.N. Cardiovascular function in acromegaly. Endocrine Reviews 24 (2003) 272-277
38. Gouya H., Vignaux O., Le Roux P., et al. Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence. AJR American Journal of Roentgenology 190 (2008) 1576-1582
39. Bihan H., Espinosa C., Valdes-Socin H., et al. Long-term outcome of patients with acromegaly and congestive heart failure. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 5308-5313
40. Colao A., Spinelli L., Marzullo P., et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. The Journal of Clinical Endocrinology and Metabolism 88 (2003) 3196-3201
41. Pereira A.M., van Thiel S.W., Lindner J.R., et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 71-75
42. Freda P.U., Shen W., Heymsfield S.B., et al. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. The Journal of Clinical Endocrinology and Metabolism 93 (2008) 2334-2343
43. Katznelson L. Alterations in body composition in acromegaly. Pituitary 12 (2009) 136-142
44. Herrmann B.L., Wessendorf T.E., Ajaj W., et al. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. European Journal of Endocrinology 151 (2004) 309-315
45. Attal P, Claes V, Bobin S, et al. Growth hormone excess and sternohyoid muscle mechanics in rats. The European Respiratory Journal, (in press, available on line).
46. ® on sleep apneoa in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clinical Endocrinology 55 (2001) 477-483
47. Melmed S. Acromegaly and cancer: not a problem?. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 2929-2934
48. Jenkins P.J., and Besser M. Clinical perspective: acromegaly and cancer: a problem. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 2935-2941
49. Renehan A.G., O'Connell J., O'Halloran D., et al. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Hormone and Metabolic Research 35 (2003) 712-725
50. Delhougne B., Deneux C., Abs R., et al. The prevalence of colonic polyps in acromegaly: a prospective colonoscopic and pathological study in 103 patients. The Journal of Clinical Endocrinology and Metabolism 80 (1995) 3223-3226
51. Trainer P.J., Barth J., Sturgeon C., et al. Consensus statement on the standardisation of GH assays. European Journal of Endocrinology 155 (2006) 1-2
52. Giustina A., Barkan A., Casanueva F.F., et al. Criteria for cure of acromegaly: a consensus statement. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 526-529
53. Cazabat L., Souberbielle J.C., and Chanson P. Dynamic tests for the diagnosis and assesment of treatment efficacy in acromegaly. Pituitary 11 (2008) 129-139
54. Dimaraki E.V., Jaffe C.A., DeMott-Friberg R., et al. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 3537-3542
55. Trainer P.J. Editorial: acromegaly-consensus, what consensus?. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 3534-3536
56. Kovacs K., Lloyd R., Horvath E., et al. Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. American Journal of Pathology 134 (1989) 345-353
57. Sakharova A.A., Dimaraki E.V., Chandler W.F., et al. Clinically silent somatotropinomas may be biochemically active. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 2117-2121
58. Dekkers O.M., Biermasz N.R., Pereira A.M., et al. Mortality in acromegaly: a metaanalysis. The Journal of Clinical Endocrinology and Metabolism 93 (2008) 61-67
59. Ayuk J., Clayton R.N., Holder G., et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 1613-1617
60. Kauppinen-Makelin R., Sane T., Reunanen A., et al. A nationwide survey of mortality in acromegaly. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 4081-4086
61. Holdaway I.M., Bolland M.J., and Gamble G.D. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology 159 (2008) 89-95
62. Holdaway I.M., Rajasoorya R.C., and Gamble G.D. Factors influencing mortality in acromegaly. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 667-674
63. Chanson P., and Maison P. Does attainment of target levels of growth hormone and insulin-like growth factor I improve acromegaly prognosis?. Nature Clinical Practice in Endocrinology and Metabolism 5 (2009) 70-71
64. Biermasz N.R., van Thiel S.W., Pereira A.M., et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 5369-5376
65. Maison P., and Chanson P. Less is more risky? Growth hormone and insulin-like growth factor 1 levels and cardiovascular risk. Nature Clinical Practice in Endocrinology and Metabolism 2 (2006) 650-651
66. Melmed S., Casanueva F.F., Cavagnini F., et al. Guidelines for acromegaly management. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 4054-4058
67. Fahlbusch R., Honegger J., and Buchfelder M. Surgical management of acromegaly. Endocrinology and Metabolism Clinics of North America 21 (1992) 669-692
68. Swearingen B., Barker II F.G., Katznelson L., et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. The Journal of Clinical Endocrinology and Metabolism 83 (1998) 3419-3426
69. Biermasz N.R., van Dulken H., and Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 4596-4602
70. Nomikos P., Buchfelder M., and Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. European Journal of Endocrinology 152 (2005) 379-387
71. Cappabianca P., Cavallo L.M., and de Divitiis E. Endoscopic endonasal transsphenoidal surgery. Neurosurgery 55 (2004) 933-940 discussion 940-931
72. Barkan A.L., Halasz I., Dornfeld K.J., et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. [see comments]. The Journal of Clinical Endocrinology and Metabolism 82 (1997) 3187-3191
73. Biermasz N.R., van Dulken H., and Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 2476-2482
74. Barrande G., Pittino-Lungo M., Coste J., et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. [In Process Citation]. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 3779-3785
75. Brada M., Burchell L., Ashley S., et al. The incidence of cerebrovascular accidents in patients with pituitary adenoma. International Journal of Radiation Oncology Biology Physics 45 (1999) 693-698
76. Mahmoud-Ahmed A.S., Suh J.H., and Mayberg M.R. Gamma knife radiosurgery in the management of patients with acromegaly: a review. Pituitary 4 (2001) 223-230
77. Attanasio R., Epaminonda P., Motti E., et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. The Journal of Clinical Endocrinology and Metabolism 88 (2003) 3105-3112
78. Castinetti F., Taieb D., Kuhn J.M., et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 4483-4488
79. Newman C.B. Medical therapy for acromegaly. Endocrinology and Metabolism Clinics of North America 28 (1999) 171-190
80. Abs R., Verhelst J., Maiter D., et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. The Journal of Clinical Endocrinology and Metabolism 83 (1998) 374-378
81. Lamberts S.W., van der Lely A.J., de Herder W.W., et al. Octreotide. The New England Journal of Medicine 334 (1996) 246-254
82. Sassolas G., Harris A.G., and James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995-Acromegaly Study Group. The Journal of Clinical Endocrinology and Metabolism 71 (1990) 391-397
83. Chanson P., Timsit J., and Harris A.G. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clinical Pharmacokinetics 25 (1993) 375-391
84. Newman C.B., Melmed S., George A., et al. Octreotide as primary therapy for acromegaly. [see comments]. The Journal of Clinical Endocrinology and Metabolism 83 (1998) 3034-3040
85. Gillis J.C., Noble S., and Goa K.L. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 53 (1997) 681-699
86. Freda P.U., Katznelson L., van der Lely A.J., et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 90 (2005) 4465-4473
87. Colao A., Ferone D., Marzullo P., et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 2779-2786
88. Chanson P., Boerlin V., Ajzenberg C., et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clinical Endocrinology 53 (2000) 577-586
89. Caron P., Beckers A., Cullen D.R., et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 99-104
90. Bevan J.S., Atkin S.L., Atkinson A.B., et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow- release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 4554-4563
91. Colao A., Ferone D., Cappabianca P., et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. JThe Journal of Clinical Endocrinology and Metabolism 82 (1997) 3308-3314
92. Mazziotti G., Floriani I., Bonadonna S., et al. Effects of somatostatin analogs on glucose homeostasis: a meta- analysis of acromegaly studies. The Journal of Clinical Endocrinology and Metabolism (2009)
93. Kopchick J.J., Parkinson C., Stevens E.C., et al. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocrine Reviews 23 (2002) 623-646
94. Trainer P.J., Drake W.M., Katznelson L., et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. [see comments]. The New England Journal of Medicine 342 (2000) 1171-1177
95. van der Lely A.J., Hutson R.K., Trainer P.J., et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358 (2001) 1754-1759
96. Jimenez C., Burman P., Abs R., et al. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. European Journal of Endocrinology 159 (2008) 517-523
97. van der Lely A.J., Muller A., Janssen J.A., et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 478-481
98. Schreiber I., Buchfelder M., Droste M., et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology 156 (2007) 75-82